Calando Finds Partner for Non-RNAi Technology, Has No Plans to Restart In-House RNAi Programs | GenomeWeb

By Doug Macron

Arrowhead Research said this week that its Calando Pharmaceuticals subsidiary has signed a deal granting the exclusive, worldwide rights to its cyclodextrin co-polymer drug-delivery technology, as well as a phase I, non-RNAi cancer drug, to Cerulean Pharma.

In doing so, Arrowhead has taken a significant step forward in its efforts to find partners for Calando's drug-development programs and delivery technologies as it struggles under a severe cash crunch.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.